What question did this study set out to answer?

This research aims to evaluate the effectiveness of 18F-flutemetamol PET/CT imaging in assessing systemic light chain amyloidosis.

December 8, 2025Blood

Visualizing systemic light chain amyloidosis with 18f-flutemetamol PET/CT: Correlation with biomarkers and clinical outcome

View Full Paper

Ask AI

Bookmark

Authors

This analysis reveals positive correlation of AL amyloidosis with biomarkers and poor clinical outcomes using PET/CT imaging.

This research aims to evaluate the effectiveness of 18F-flutemetamol PET/CT imaging in assessing systemic light chain amyloidosis.
Patients with known or suspected AL amyloidosis were enrolled from 2022 to 2024.
Images were obtained from skull to upper thighs to assess FMM uptake in various organs.
Clinical parameters and lab results were collected to analyze relationships with survival outcomes.
36 patients with histologically proven AL amyloidosis were analyzed.
Positive FMM uptake was noted in 97% of patients, correlating with biomarkers such as NT-proBNP and troponin I.
Increased myocardial FMM uptake and involvement of multiple organs were associated with worse overall survival.

Park et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark